Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;19(7):458-470.
doi: 10.1038/s41571-022-00631-3. Epub 2022 Apr 19.

Integrated MRI-guided radiotherapy - opportunities and challenges

Affiliations
Review

Integrated MRI-guided radiotherapy - opportunities and challenges

Paul J Keall et al. Nat Rev Clin Oncol. 2022 Jul.

Abstract

MRI can help to categorize tissues as malignant or non-malignant both anatomically and functionally, with a high level of spatial and temporal resolution. This non-invasive imaging modality has been integrated with radiotherapy in devices that can differentially target the most aggressive and resistant regions of tumours. The past decade has seen the clinical deployment of treatment devices that combine imaging with targeted irradiation, making the aspiration of integrated MRI-guided radiotherapy (MRIgRT) a reality. The two main clinical drivers for the adoption of MRIgRT are the ability to image anatomical changes that occur before and during treatment in order to adapt the treatment approach, and to image and target the biological features of each tumour. Using motion management and biological targeting, the radiation dose delivered to the tumour can be adjusted during treatment to improve the probability of tumour control, while simultaneously reducing the radiation delivered to non-malignant tissues, thereby reducing the risk of treatment-related toxicities. The benefits of this approach are expected to increase survival and quality of life. In this Review, we describe the current state of MRIgRT, and the opportunities and challenges of this new radiotherapy approach.

PubMed Disclaimer

References

    1. Barton, M. B. et al. Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012. Radiother. Oncol. 112, 140–144 (2014). - PubMed - DOI
    1. Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021). - PubMed - DOI
    1. Batumalai, V. et al. Estimating the cost of radiotherapy for 5-year local control and overall survival benefit. Radiother. Oncol. 136, 154–160 (2019). - PubMed - DOI
    1. Chen, A. B., Neville, B. A., Sher, D. J., Chen, K. & Schrag, D. Survival outcomes after radiation therapy for stage III non-small-cell lung cancer after adoption of computed tomography-based simulation. J. Clin. Oncol. 29, 2305–2311 (2011). - PubMed - DOI
    1. Liao, Z. X. et al. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 76, 775–781 (2010). - PubMed - DOI

Publication types

MeSH terms

LinkOut - more resources